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The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF)
and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple
myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by
ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related
clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor
mass. The value of OPN was significantly higher in MM patients with evident bone lesions (𝑃 = 0.03) and there was also a positive
correlation with serum beta-2 microglobulin (𝑟 = 0.366; 𝑃 = 0.04). Furthermore, patients with lower Durie-Salmon stage had
significantly lower OPN and VEGF levels (𝑃 = 0.05; 𝑃 = 0.04, resp.). Our preliminary results found positive association between
plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of
OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target
for pharmacological intervention.
1. Introduction
Multiple myeloma (MM) is a common haematological neo-
plasm with heterogeneous clinical manifestations, course of
disease, response to treatment, and survival [1]. This unpre-
dictable biological behaviour is a consequence of remarkably
interesting, complex, and still unclear biological interactions
between neoplastic plasma cells and other components of
bone marrowmicroenvironment. Despite the great improve-
ment in antitumor and supportive therapy, MM still remains
an incurable disease. Vascular endothelial growth factor
(VEGF) is considered one of the most potent angiogenic
promoters in many solid tumours [2–6]. According to pre-
vious studies, it plays an angiogenic and tumorigenic role in
the pathophysiology of MM [7–9], but the significance of its
plasma level is still not well recognized. VEGF is produced
by malignant plasma cells, as well as various inflammatory
and stromal cells, acting through autocrine and/or paracrine
crosstalk via their VEGFR-1 and VEGFR-2 receptors [7, 8, 10,
11].
Osteopontin (OPN) is a multifunctional, acid-rich, non-
collagenous glycol-phosphoprotein expressed in bone, which
interacts with integrin and CD44 receptors [12–14]. The
binding of OPN to these surface receptors can elicit extensive
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changes in cell functions, such as enhanced mobility and
adhesion, accelerated growth and division, prolongation of
cell survival, and angiogenesis [15]. It is involved in a variety
of physiological and pathological processes including inflam-
mation, ischemia-reperfusion, bone resorption, atherosclero-
sis, and tumour progression [15]. In many types of human
cancers the overexpression of OPN in tumour tissue or in
blood has been associated with more advanced disease and
recently it has been shown that OPN has the value as a
clinical tumour progression marker [16]. It is well known
that different stromal elements such as endothelial cells,
macrophages, especially osteoclasts, lymphocytes, smooth
muscle cells, andmyeloma cells have potential to secreteOPN
[17, 18].There is a growing evidence for the role of OPN in the
bone destruction and angiogenesis of MM [18–21].
However, until now, only a very few studies have partially
explored associations between plasma levels of VEGF and
OPN with some of the clinical features and parameters of
tumor burden in myeloma patients [18–22]. In this pilot
investigation we tried to detect possible association of plasma
OPNandVEGFwithmyeloma related clinicalmanifestations
such as anemia, renal dysfunction, and bone disease, aswell as
with serum beta-2 microglobulin and Durie-Salmon clinical
stage which are prognosticators related to tumour burden.
2. Patients and Methods
2.1. Patients. We retrospectively analyzed 44 newly diag-
nosed, previously untreated myeloma patients (21 males, 23
females; median age of 69 years; age range 44–86 years)
and 24 age-matched healthy individuals as a control group
(12 males, 12 females; median age of 67 years; age range
35–83 years). Diagnoses were established at the Department
of Hematology, Clinical Centre Rijeka, during the period
from 2010 to 2012, according to the International Myeloma
Working Group Criteria [23]. The control group consisted of
healthy volunteers who were treated in the outpatient clinic
hematology because of altered blood findings but none of
them had any hematological disease. Patients with liver or
renal impairment, current or previous other malignancies,
infectious diseases, or incapability to consent were excluded
from the control group. Blood samples were collected at the
time of diagnosis from all MM patients, before the initi-
ation of any antimyeloma treatment, including supportive
treatment (e.g., bisphosphonate administration). All blood
samples, collected from patients and controls, were aliquoted
into separate vials, stored at −20∘C, and assayed at the end
of the study, in order to avoid interassay variability. Written
informed consentwas obtained fromeach patient andhealthy
volunteer prior to their inclusion in the study. The study was
approved by the local ethics committee.
Patients were categorized according to Durie-Salmon
clinical stage [24]. Because of the small number of cases in
each Durie-Salmon stage group, we grouped clinical stages I
and II together and compared them to stage III with the intent
of separating patients with the largest tumor mass. The main
characteristics of our patients are summarized in Table 1.
Table 1: Clinical features of patients with multiple myeloma (MM)
and healthy volunteers who form the control group.
Clinical features Patients with MM(𝑁 = 44)
Healthy control group
(𝑁 = 24)
Age and sex
distribution Cases Cases
Male 21 12
Female 23 12
Age (years) Median 69 Median 67
Range 44–86 Range 35–83
Durie-Salmon stage Cases
I 7
II 8
III 29
Renal dysfunction Cases
Yes 11
No 32
Anemia Cases
Yes 31
No 13
Beta-2
microglobulin Cases
Normal 9
Increased 33
Bone disease Cases
Yes 32
No 10
Note: renal dysfunction = serum creatinine level above the upper limit of
normal; anemia = haemoglobin value 20 g/L below the lower limit of normal;
beta-2 microglobulin = normal values less than 2.5 𝜇g/mL versus increased
plasma values; and bone disease = presence of any lytic lesion or severe
osteopenia with compressive fractures on standard radiographs of the bones.
The obtained plasma cytokine levels were correlated with
main clinical manifestations in MM: anemia (hemoglobin
20 g/L below the lower limit of normal, defined as 138 g/L
for men and 119 g/L for women), renal dysfunction (serum
creatinine level above the upper limit of normal, defined as
117 𝜇mol/L for men and 96 𝜇mol/L for women), and bone
disease (the presence of any lytic lesion or severe osteopenia
with compressive fractures on standard radiographs of the
bones). The values of OPN and VEGF were also correlated
with serum beta-2 microglobulin and with Durie-Salmon
clinical stage (stages I and II combined versus stage III) as
a measure of tumor mass.
2.2. Measurement of Cytokines. The concentrations of OPN
and VEGF were determined in plasma samples by enzyme-
linked immunoassay (ELISA, Quantikine RD Systems, Min-
neapolis, MN, USA) according to the manufacturer’s instruc-
tions. In brief, these assays employ the quantitative sandwich
immunoassay technique. A monoclonal antibody specific
for protein was precoated onto microplates. Standards and
samples were pipetted into the wells. After binding and
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Table 2: Comparison of measured plasma OPN and VEGF levels with clinical parameters in patients with MM.
Durie-Salmon stage
𝑃 value Bone lesions 𝑃 value Anemia 𝑃 value Renal dysfunction 𝑃 value
I, II III Yes No Yes No Yes No
OPN (ng/mL)
Median 5.65 8.9 0.05 7.4 2.8 0.03 7.6 6.6 0.29 12.6 7.05 0.13
Range 0.3–14.6 2.2–26.5 3.3–26.5 0.3–12.9 0.3–26.5 2.3–12.9 3.7–26.5 0.3–22.2
VEGF (pg/mL)
Median 35.9 60.15 0.04 48.1 55.75 0.79 57.4 47 0.43 46.9 59 0.51
Range 5.3–111.7 20.3–178.9 5.3–178.9 22.6–111.7 5.3–178.9 29.2–69.2 20.3–148.9 5.3–178.9
washing, an enzyme-linked polyclonal antibody specific for
each growth factor was added to each well. After a wash to
remove any antibody-enzyme reagent, a substrate solution
was added to the wells and color developed in proportion to
the amount of each growth factor that was bound in the first
step. The color development was stopped and optical density
of each well was measured using the microplate reader set at
450 nm. The concentration of each specific growth factor in
each plasma sample was calculated from standard curves and
reported in pg/mL for VEGF and ng/mL for OPN.
2.3. Statistical Analysis. Statistical analyses were performed
using MedCalc for Windows, version 12.2.1.0 (MedCalc
Software, Ostend, Belgium). The distribution of data was
tested for normality using the Kolmogorov-Smirnov test.The
measures of central tendency for continuous data such as
OPN and VEGF values were compared by Student’s 𝑡-test
or Mann-Whitney 𝑈 test, depending on data distribution.
The independent 𝑡-test and Mann-Whitney 𝑈 test were used
to assess whether continuous variables differed significantly
between categories (patients with bone lesions versus patients
without bone lesions, Durie-Salmon clinical stages I and II
versus stage III, patients with anemia versus patients without
anemia, etc.). Correlation between continuous variables was
studied using Pearson correlation. Statistical differences with
𝑃 < 0.05 were considered significant.
3. Results
Certain amounts of both cytokines, OPN and VEGF, were
detected in plasma samples from all patients. In addition,
OPN value was significantly higher in MM patients (median
6.5 ng/mL, range 0.3–21.7 ng/mL) in comparison with the
control group (median 2.4 ng/mL, range 0.2–8.9 ng/mL;
𝑃 < 0.0001; Figure 1). Such differences were not observed
regarding VEGF (median 52.5 pg/mL, range 5.3–178.9 pg/mL
in MM patients versus median 60.5 pg/mL, range 12.2–
205.6 pg/mL in control group; 𝑃 = 0.67).
In contrast with VEGF, plasma OPN levels were signifi-
cantly higher in patients with evident bone lesions (𝑃 = 0.03;
Figure 2). However, there were no statistically significant
differences in levels of the analyzed cytokines in patients
with anemia and renal insufficiency compared to those
without these myeloma related complications. Further aim
was to compare plasma levels of OPN and VEGF with
parameters of tumor burden, and statistically significant
O
PN
 (n
g/
m
L)
0
5
10
15
20
25
MM Healthy
∘
∘
Figure 1: Comparison of plasma OPN levels between patients with
MMand healthy volunteers who form the control group.The plasma
concentrations of OPN were significantly higher in MM patients
than in healthy volunteers (𝑃 < 0.0001, Mann-Whitney 𝑈 test).
The upper and lower borders of the box indicate the 75th and
25th percentiles, respectively, and the line in the box represents
the median. The ends of the whiskers represent the minimum and
maximum of all of the data excluding outliers. Outliers are plotted
as individual points.
differences amongDurie-Salmon stages were observed.More
specifically, patients in stages I and II had significantly lower
plasma OPN (𝑃 = 0.05) and lower plasma VEGF (𝑃 =
0.04) values compared to patients in stage III of the dis-
ease. Furthermore, a significant positive correlation between
plasma OPN concentration and serum beta-2 microglobulin
level (𝑟 = 0.366; 𝑃 = 0.04) was determined, while there
was no correlation for VEGF plasma values. The results are
summarized in Table 2.
4. Discussion
There is a certain body of evidence demonstrating the
involvement ofVEGF andOPN in angiogenesis and bone dis-
ease during MM progression. However, little is known about
the possible clinical significance of plasma OPN and VEGF
regarding other aspects of disease. As we know, myeloma
is a collection of related disorders rather than a single
disease. For that reason, the present study was conducted
with the purpose of correlating serum concentrations of these
4 BioMed Research International
O
PN
 (n
g/
m
L)
0
5
10
15
20
25
30
Yes
Bone lesion
No
∘
Figure 2: Comparison of plasma OPN levels between patients with
bone disease and those without manifest bone lesions. The plasma
concentrations of OPN were significantly higher in patients with
bone disease (𝑃 = 0.03, Mann-Whitney 𝑈 test). The upper and
lower borders of the box indicate the 75th and 25th percentiles,
respectively, and the line in the box represents the median.The ends
of the whiskers represent the minimum and maximum of all of the
data excluding outliers. Outliers are plotted as individual points.
cytokines with the most common presenting symptoms of
MM (e.g., anemia, renal insufficiency, and bone disease), as
well as with routine prognosticators beta-2 microglobulin
andDurie-Salmon clinical stage, which reflect tumor burden.
The first result of this study revealed significantly higher
plasma OPN in myeloma patients than in healthy controls.
This finding agrees with some [25, 26], but not all, inves-
tigations [20, 27]. Furthermore, Saeki et al., Scudla et al.,
and Minarik et al. have observed differences in plasma OPN
levels between monoclonal gammopathy of undetermined
significance and MM [26, 28–30]. All of these results taken
together implicate OPN in the biology of MM. Although
several groups have demonstrated significantly increased
plasma VEGF among myeloma patients in comparison with
control groups [31–33], our current study and Sezer et al. [34]
did not confirm this finding.
Our second finding revealed the associations of plasma
concentrations of both VEGF and OPN with Durie-Salmon
clinical stage. Plasma levels of both cytokines were signifi-
cantly elevated in stage III compared with stages I and II.
This positive association between cytokine values and Durie-
Salmon clinical stage is not unexpected and is likely related to
tumor burden. If that assumption is correct, the plasma levels
of these cytokines (which can be produced by malignant
plasma cells) might represent a measure of myeloma cell
mass, not unlike the Durie-Salmon Staging System, which is
based on a mathematical model for estimating the number
of tumor cells. This result is in accordance with the finding
that VEGF can act directly or indirectly as a growth factor
for myeloma cells, which has been reported previously by
some authors [7, 35, 36]. In addition, the present study
demonstrated a significant positive association betweenOPN
and another prognostic factor related to tumor burden and
aggressive biological behavior of MM- beta-2 microglobulin,
as previously described [20, 22]. However, we did not find the
same association between VEGF and beta-2 microglobulin,
which is intriguing and can be attributed to the relatively
small number of cases included in this study. Still, it is possible
that beta-2 microglobulin, in addition to myeloma cell mass
and renal filtering capacity, might also reflect some other
as-yet-unrecognized aspects of myeloma biology because,
in contrast to Durie-Salmon clinical stage, it has retained
prognostic value in the era of novel therapeutic agents.
We also observed significantly increased plasma OPN
levels among myeloma patients with overt bone disease
in comparison to those who had normal bone radiologic
findings. Few groups have been able to demonstrate the
same results [20, 22, 26]. Conversely, Robbiani and his group
proposed that MM-derived OPN plays a critical role in bone
disease by protecting bone from destruction [18]. Hence,
the results of this study support the idea that OPN is an
important pathophysiological factor in the biology of MM
involved in bone disease. In addition, its positive association
with parameters of tumor burden might suggest a role in
the proliferation and survival of myeloma cells which should
be explored in the future. All of this information affords us
the opportunity to modulate its role in the tumor ecosystem
through different pharmacological interventions.
According to our knowledge, only Dizdar et al. have
investigated and proven a positive correlation between OPN
and serum creatinine [22]. In contrast, we did not observe any
relationship betweenplasmaOPN level and renal impairment
or anemia, which suggests that thismultifunctional phospho-
protein is not relevantly involved in these aspects of MM.
Moreover, our study reveals that plasma VEGF level was not
associated with any of the main clinical features of MM or
beta-2 microglobulin, a finding that is in concordance with
the findings of other studies [32, 34]. Still, Di Raimondo et al.
have observed that plasma VEGF levels correlate positively
with beta-2 microglobulin, but not with osteolytic lesions,
hemoglobin concentration, or creatinine concentration [9].
One question is whether plasma OPN (or VEGF) levels
objectively reflect their concentrations in bone marrow,
where the tumor is actually growing. Previous studies have
shown that the concentrations of investigated angiogenic fac-
tors were higher in bone marrow but correlated significantly
with plasma levels [9, 37].
Important limitations of present study are rather small
sample size with missing clinical data for some patients, as
well as its retrospective design, which limits any definite
conclusions.
5. Conclusion
Our preliminary results support plasmaOPN level as a possi-
ble marker of bone destruction. Although VEGF reportedly
represents a critical angiogenic factor in the tumor microe-
cosystem, the present study did not suggest that plasma
VEGF level has similar clinical value to OPN. Furthermore,
we did not observe associations between plasma levels of
the investigated cytokines and other clinical features of MM,
such as anemia or renal impairment. However, in the present
pilot study, both cytokines were positively associated with
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tumor burden. Further prospective analysis of a larger group
of patients should provide definitive information about the
possible role of OPN as a useful clinical biomarker for
monitoring bone disease and tumor mass, as well as a
prognostic factor during the course of MM.
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